TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in France, Germany, and Italy. Primary objective: to assess the time patients remained on their first GLP-1 RA without a significant treatment change due to treatment- or diabetes-related factors. Kaplan-Meier (KM) probability (95% CI) of no significant treatment change at 24 months was 0.71 (0.68-0.74) and 0.53 (0.49-0.56) in the DU and LIRA cohorts, respectively (Figure) . Two-hundred and eighty-six (28.2%) and 448 (45.2%) patients receiving DU and LIRA, respectively, had a significant treatment change. The main driver of treatment change in the DU and LIRA cohorts was intensification with an add-on therapy (insulin or OAD) and intensification with dose increase of GLP-1 RA, respectively. KM probability (95% CI) of GLP-1 RA persistence at 24 months was high in both cohorts: DU 0.82 (0.80-0.85) ; LIRA 0.75 (0.72-0.78) .

In summary, the probabilities of no significant treatment change over 24 months were estimated as higher in the DU cohort than in the LIRA cohort in this non-comparative analysis, with good persistence in both cohorts.

Disclosure

F. Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Lilly Diabetes, Sanofi. Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. B. Guerci: Advisory Panel; Amgen Inc., Medtronic. Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. L. Garcia-Perez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Fuechtenbusch: Advisory Panel; Berlin-Chemie AG. Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp. Speaker's Bureau; AstraZeneca, Novo Nordisk. J. Lebrec: Consultant; Eli Lilly and Company. M. Orsini Federici: Employee; Eli Lilly and Company. A. Dib: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. E. Heitmann: None. M. Yu: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. K. Boye: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.